Poolbeg Pharma #POLB – AI programme yields novel RSV drug targets March 29, 2022 – Posted in: Poolbeg Pharma (POLB)

  AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV   8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with partner OneThree Biotech , Inc. through…

Continue reading

Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets March 28, 2022 – Posted in: Poolbeg Pharma (POLB)

  Poolbeg Pharma PLC #POLB – AI programme yields novel RSV drug targets Artificial intelligence programme yields multiple novel RSV drug targets First time AI has been used to identify disease targets in RSV 8 November 2022 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that it has made a significant breakthrough in its Artificial Intelligence (‘AI’) Programme with…

Continue reading

Tiziana Life Sci (TILS) Issue of Equity and Directorate Change November 20, 2019 – Posted in: Tiziana Life Sciences (TILS)

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 20 November 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has issued 190,698 ordinary shares of 3p each (“Ordinary Shares”) credited as fully paid at a price of 43p per share in satisfaction of a…

Continue reading